readthroughSign in
Nov 10, 2026Quarterly update

Eupraxia hits enrollment target in Phase 2b EoE trial, sets December readout

The company completed enrollment of 120 patients in the placebo-controlled portion of its RESOLVE trial and expects interim results in December 2026, with cash guided into the second half of 2028.

Eupraxia Pharmaceuticals announced third quarter 2026 results on November 10, 2026, reporting that it had reached its target enrollment of 120 patients in the placebo-controlled blinded Phase 2b portion of the RESOLVE trial on October 15, 2026.1 The company said interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.1

The Phase 2b study is testing EP-104GI, an injectable local-delivery drug candidate, in Eosinophilic Esophagitis (EoE). This randomized placebo-controlled portion of RESOLVE is evaluating both the 120mg (20x6mg) and 160mg (20x8mg) doses.1

Separately, in the open-label Phase 1b/2a portion of RESOLVE, the company reported new data during the quarter. On September 30, 2026, the company announced 52-week data from the highest dose cohort (Cohort 9; n=3), which showed durability of symptom responses out to 52 weeks, with 66% of patients (2 of 3) maintaining clinical remission.1 Across a broader analysis, 64% of patients remained in clinical remission over the 52-week period, along with what the company described as clinically meaningful histologic improvements.1

The company also disclosed symptom data on painful swallowing. On August 13, 2026, it announced new data on Odynophagia from the ongoing Phase 1b/2a RESOLVE trial, showing the number of patients with moderate to severe odynophagia in Cohorts 7-9 (n=13) fell from 62% at baseline to 25% from 24 through 52 weeks post-treatment.1

On the corporate side, the company completed a transfer to the Nasdaq Global Select Market on September 8, 2026.1

Financially, Eupraxia held cash and cash equivalents of $75.2 million and short-term investments of $51.2 million as of September 30, 2026, up from a cash balance of $80.6 million at the end of the fourth quarter of 2025.1 The company said it anticipates existing cash reserves will be sufficient to fund the company into the second half of 2028.1 The quarterly net loss widened to $15.2 million for the three months ended September 30, 2026, versus $6.4 million a year earlier, which the company attributed primarily to higher research and development costs tied to doubling the size of the Phase 2b RESOLVE trial, along with increased general and administrative costs.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.